IP Library › Granted Patent US 12,371,522
Granted Patent B2
US 12,371,522 · App. 14/438,353 · Granted Jul 29, 2025

Bioreducible poly (beta-amino ester)s for siRNA delivery

Inventors: Jordan J Green (Nottingham, MD); Kristen Kozielski (Baltimore, MD); Stephany Yi Tzeng (Baltimore, MD)
Assignee: The Johns Hopkins University
C08F222/14A61K9/5153A61K31/713A61K47/32A61K47/595A61K47/6921A61L27/18A61L27/38A61L27/56A61L27/58A61L31/10A61L31/148C07C323/12C07D295/125C08G73/0253C12N15/88Y10T428/2982
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,371,522
App. No.
14/438,353
Granted
Jul 29, 2025
Kind
B2
Abstract

Degradable polymers were synthesized that self-assemble with nucleic acids, proteins, hydrophobic drugs, and other small molecules to form particles that are effective for delivery into a cell, tissue and/or organism either in vitro or in vivo. The presently disclosed polymers demonstrate differential cell-type specificity, an ability to promote endosomal escape to protect the cargos from degradation and enhance delivery to the cytoplasm, and/or bioreducibility, which enables triggered intracellular drug release to be tuned to promote optimal delivery to the target cell type. The presently disclosed materials may be used to treat a wide variety of conditions or diseases, such as cancer, cardiovascular diseases, infectious diseases, and ophthalmic diseases.

Claims (41)

1. A nanoparticle or microparticle comprising siRNA or miRNA and a compound of formula (I) or formula (II):

wherein:

n is an integer from 1 to 10,000;

X and Y are integers selected from 1 and 3;

Z is an integer from 1 to 10,000;

R 1 and R 2 can be the same or different and are each independently a C 1 -C 30 alkyl chain;

each R 3 is a C 3 -C 8 linear or branched alkyl chain;

R′ is a side chain derived from:

the R″ end groups are the same or different and are derived from a compound selected from the group consisting of:

or R″ comprises a biomolecule selected from the group consisting of poly(ethyleneglycol) (PEG), a targeting ligand, and a labeling molecule, or R″ comprises a C 1 -C 30 alkyl chain, wherein the C 1 -C 30 alkyl chain is terminated with a functional group selected from the group consisting of —OH and —NH 2 ; and

pharmaceutically acceptable salts thereof.

2. The nanoparticle or microparticle of claim 1 , wherein the compound from which the same or different R″ end groups are derived is selected from the group consisting of:

3. The nanoparticle or microparticle of claim 1 , wherein the compound of formula (I) has the following structure:

4. The nanoparticle or microparticle of claim 1 , wherein the targeting ligand is selected from the group consisting of a sugar, a small molecule, an antibody, an antibody fragment, and a peptide.

5. The nanoparticle or microparticle of claim 1 , wherein the labeling molecule is selected from the group consisting of a small molecule, a quantum dot, a nanoparticle, a fluorescent molecule, a luminescent molecule, and a contrast agent.

6. The nanoparticle or microparticle of claim 1 , wherein the PEG has a molecular weight between about 5 kDa and about 30 kDa.

7. The nanoparticle or microparticle of claim 1 , wherein n is an integer selected from the group consisting of from 1 to 1,000, from 1 to 100, from 1 to 30, from 5 to 20, and from 10 to 15.

8. The nanoparticle or microparticle of claim 1 , wherein the compound of formula (I) or formula (II) is crosslinked.

9. A pharmaceutical composition comprising the nanoparticle or microparticle of claim 1 .

10. A method for treating a disease or condition, the method comprising administering to a subject in need thereof, the nanoparticle or microparticle of claim 1 or a pharmaceutical composition thereof.

11. The method of claim 10 , wherein the disease or condition is selected from the group consisting of a cancer, a cardiovascular disease, an infectious disease, and an ophthalmic disease.

12. A method of delivering siRNA or miRNA to a cell, a cell line, a tissue, or an organism, the method comprising contacting one or more of the nanoparticles or microparticles of claim 1 with the cell, cell line, tissue or organism.

13. The method of claim 12 , wherein the siRNA or miRNA is released from the one or more nanoparticles or microparticles after entering the cell, binds to its complementary mRNA, and the complementary mRNA is cleaved.

14. The method of claim 13 , wherein the siRNA or miRNA is released from the one or more nanoparticles or microparticles while the compound of formula (I) or formula (II) is degrading, thereby allowing sustained release of the siRNA or miRNA.

15. The method of claim 12 , wherein the one or more nanoparticles or microparticles enter the cytoplasm of the cell.

16. The method of claim 15 , wherein the compound of formula (I) or formula (II) is degraded reductively in the cytoplasm to release the siRNA or miRNA in the cytoplasm.

17. The method of claim 16 , wherein at least one disulfide bond of the compound of formula (I) or formula (II) is degraded reductively in the cytoplasm.

18. The method of claim 17 , wherein the at least one disulfide bond is degraded reductively by glutathione.

19. A kit comprising the nanoparticle or microparticle compound of claim 1 or a pharmaceutical composition thereof.

20. A biomedical device comprising the nanoparticle or microparticle of claim 1 or a pharmaceutical composition thereof.

21. The biomedical device of claim 20 , wherein the biomedical device comprises a stent or a stent-like device.

22. The nanoparticle or microparticle of claim 1 , wherein the nanoparticle or microparticle has at least one dimension ranging from about 1 nm to about 300 nm.

23. The nanoparticle or microparticle of claim 22 , wherein the nanoparticle or microparticle has at least one dimension of about 100 nm.

24. A method of storing the nanoparticle or microparticle of claim 1 , the method comprising adding a cryoprotectant to the nanoparticle or microparticle to form a mixture and lyophilizing the mixture to form storable powder of the nanoparticle or microparticle.

25. The method of claim 24 , wherein the cyroprotectant comprises a sugar.

26. A method of silencing a gene in a cell, the method comprising contacting the cell with one or more of the nanoparticles or microparticles of claim 1 , wherein the one or more nanoparticles or microparticles enter the cytoplasm of the cell, wherein the compound of formula (I) or formula (II) is reductively degraded in the cytoplasm thereby releasing the siRNA or miRNA from the one or more nanoparticles or microparticles, thereby silencing the gene.

27. The method of claim 26 , wherein at least one disulfide bond of the compound of formula (I) or formula (II) is degraded reductively in the cytoplasm.

28. The method of claim 27 , wherein the at least one disulfide bond is degraded reductively by glutathione.

29. The method of claim 11 , where in the cancer is selected from the group consisting of brain cancer, lung cancer, breast cancer, prostate cancer, and colorectal cancer.

30. The method of claim 29 , wherein the brain cancer is Glioblastoma Multiforme.

31. The method of claim 11 , wherein the ophthalmic disease is age-related macular degeneration.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2025
From: TZENG, STEPHANY YI
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 070487/0209 →
CONFIRMATORY LICENSE Recorded Mar 7, 2018
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045518/0176 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2016
From: GREEN, JORDAN J.; KOZIELSKI, KRISTEN
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 037552/0390 →
Continuity (6)
Continuation In Part 13272042 · Oct 12, 2011
Provisional Application 61883376 · Sep 27, 2013
Provisional Application 61860638 · Jul 31, 2013
Provisional Application 61718536 · Oct 25, 2012
Related Publication 20150273071A1 · Oct 1, 2015
Related Publication 20190209690A9 · Jul 11, 2019
References Cited (100)
US 5948878A · Burgess · 1999 [cited by applicant]
US 20020141965A1 · Ahn · 2002 [cited by applicant]
US 20080299177A1 · Hardy · 2008 [cited by applicant]
US 20100178305A1 · Rapoport · 2010 [cited by applicant]
US 20100204297A1 · Chen · 2010 [cited by examiner]
US 20110076307A1 · Jin · 2011 [cited by applicant]
US 20120114759A1 · Green · 2012 [cited by applicant]
US 20120128782A1 · Green · 2012 [cited by applicant]
US 20130211249A1 · Barnett et al. · 2013 [cited by applicant]
US 20140341803A1 · Rapoport · 2014 [cited by applicant]
CA 2304134 · 1999 [cited by applicant]
WO 2007020060A1 · 2007 [cited by applicant]
WO 2007086923A2 · 2007 [cited by applicant]
WO 2010132879A2 · 2010 [cited by applicant]
WO 2011078805A1 · 2011 [cited by applicant]
Yin et al., J. Control. Rel., online Jan. 16, 2011, 151: 35-44. [cited by examiner]
Kim et al., Bioconjugate Chem., 2005, 16: 1140-1148. [cited by examiner]
Sunshine et al., Adv. Mater., 2009, 21: 4947-4951. [cited by examiner]
Pfeifer et al., Int. J. Pharm., 2005, 304: 210-219. [cited by examiner]
Vandenbroucke et al., J. Gene Med., 2008, 10: 783-794. [cited by examiner]
Kuwabara, P. E. et al. RNAi-prospects for a general technique for determining gene function. Parasitol Today 2000, 16, 347-9. [cited by applicant]
Lynn, D. M., et al. Degradable poly (B-amino esters): synthesis, characterization, and self-assembly with plasmid DNA. Journal of the American Chemical Society 2000, 122, 44, 10761-10768. [cited by applicant]
Sunshine, J. C., et al. Uptake and Transfection with Polymeric Nanoparticles are Dependent on Polymer End-Group Structure, but Largely Independent of Nanoparticle Physical and Chemical Properties. Molecular Pharmaceutic… [cited by applicant]
Griffith, O. W. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radical Biology and Medicine 1999, 27, 922-935. [cited by applicant]
Chen, J. et al. pH and Reduction Dual-Sensitive Copolymeric Micelles for Intracellular Doxorubicin Delivery. Biomacromolecules, 2011, 12, 3601-11. [cited by applicant]
T. G. Park, J. H. Jeong, and S. W. Kim, “Current status of polymeric gene delivery systems, ” Advanced Drug Delivery Reviews, vol. 58, pp. 467-486, 2006. [cited by applicant]
Pack, D. et al, “Design and development of polymers for gene delivery,” Nature Reviews Drug Discovery, vol. 4, pp. 581-593, 2005. [cited by applicant]
Akinc, A. et al, “Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis, ” Journal of Gene Afedicine, vol. 7, pp. 657-663, May 2005. [cited by applicant]
Putnam, D. et al, “Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain tennini,” Proc Natl Acad Sci USA, vol. 98, pp. 1200-1205, Jan. 30, 2001. [cited by applicant]
Moghimi, S. et al, “A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy,” Afol Ther, vol. 11, pp. 990-995, Jun. 2005. [cited by applicant]
Akinc, A. et al, “Parallel synthesis and biophysical characterization of a degradable polymer library for gene delivery,” Journal of the American Chemical Society, vol. 125, pp. 5316-5323, May 7, 2003. [cited by applicant]
Green, J. et al, “Biodegradable polymeric vectors for gene delivery to human endothelial cells,” Bioconjugate Chemistry, vol. 17, pp. 1162-1169, 2006. [cited by applicant]
Akinc, A. et al, “Synthesis of poly(beta-amino ester)s optimized for highly effective gene delivery,” Bioconjugate Chemistry, vol. 14, pp. 979-988, Sep.-Oct. 2003. [cited by applicant]
Green, J. et al, “Combinatorial modification of degradable polymers enables transfection of human cells comparable to adenovirus,” Advanced A1aterials, vol. 19, pp. 2836-2842, 2007. [cited by applicant]
Gosselin, M. et al, “Efficient gene transfer using reversibly cross-linked low molecular weight polyethylenimine,” Bioconjugate Chemistry, vol. 12, pp. 989-994, Nov.-Dec. 2001. [cited by applicant]
Forrest, M. et al, “A degradable polyethylenimine derivative with low toxicity for highly efficient gene delivery,” Bioconjug Chem, vol. 14, pp. 934-940, Sep.-Oct. 2003. [cited by applicant]
Christensen, L. et al, “Reducible poly(amido ethylenimine)s designed for triggered intracellular gene delivery,” Bioconjugate Chemistry, vol. 17, pp. 1233-1240, Sep.-Oct. 2006. [cited by applicant]
Lin, C. et al, “Bioreducible poly(amido amine)s with oligoamine side chains: synthesis, characterization, and structural effects on gene delivery,” Journal of Controlled Release, vol. 126, pp. 166-174, Mar. 3, 2008. [cited by applicant]
Yu, J. et al, “Induced pluripotent stem cell lines derived from human somatic cells,” Science, vol. 318, pp. 1917-1920, Dec. 21 2007. [cited by applicant]
Yadav, S., et al. “Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells”Cancer Chemother. Ph… [cited by applicant]
Akinc, A., et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 2008, 26, (5), 561-569. [cited by applicant]
Semple, S. et al, “Rational design of cationic lipids for siRNA delivery” J. Nat. Biotechnol. 2010, 28, (2), 172-6. [cited by applicant]
Derfus, A. et al. “Targeted Quantum Dot Conjugates for siRNA Delivery” Bioconjugate Chem. 2007, 18, (5), 1391-1396. [cited by applicant]
Elbakry, A. et al. “Layer-by-layer assembled gold nanoparticles for siRNA delivery” Nano Lett. 2009, 9, (5), 2059-2064. [cited by applicant]
Kakizawa, Y., et al. “Organic-inorganic hybrid-nanocarrier of siRNA constructing through the self-assembly of calcium phosphate and PEG-based block aniomer” J. Control. Release 2006, 111, (3), 368-370. [cited by applicant]
Breunig, M., et al. “Mechanistic investigation of poly (ethylene imine)-based siRNA delivery: disulfide bonds boost intracellular release of the cargo” J. Control Release 2008, 130, (1), 57-63. [cited by applicant]
Jeong, J. H., “Reducible poly(amido ethylenimine) directed to enhance RNA interference” Biomaterials 2007, 28, (10), 1912-1917. [cited by applicant]
Matsumoto, S., et al. “Environment-Responsive Block Copolymer Micelles with a Disulfide Cross-Linked Core for Enhanced siRNA Delivery” Biomacromolecules 2009, 10, (1), 119-127. [cited by applicant]
Hagerman, P., “Flexibility of RNA” J. Annu. Rev. Biophys. Biomol. Struct. 1997, 26, 139-156. [cited by applicant]
Kebbekus, P., et al “Persistence Length of RNA” Biochemistry 1995, 34, (13), 4354-4357. [cited by applicant]
Miyata, K., et al. “Block Catiomer Polyplexes with Regulated Densities of Charge and Disulfide Cross-Linking Directed to Enhance Gene Expression” J. Am. Chem. Soc. 2004, 126, (8), 2355-2361. [cited by applicant]
Tzeng, S., et al “Cystamine-terminated poly(beta-amino ester)s for siRNA delivery to human mesenchymal stem cells and enhancement of osteogenic differentiation” Biomaterials 2012, 33, (32), 8142-8151. [cited by applicant]
Bhise, N., et al. “A novel assay for quantifying the numbers of plasmids encapsulated by polymer nanoparticles” Small 2012, 8, (3), 367-373. [cited by applicant]
Yin, Q. et al. Bioreducible poly (B-amino esters)/shRNA complex nanoparticles for efficient RNA delivery. Journal of Controlled Release 151 (2011) 35-44. [cited by applicant]
Kim, T. et al. Bioreducible polymers for gene delivery. Reactive & Functional Polymers 71 (2011) 344-349. [cited by applicant]
Son, S. et al. Bioreducible Polymers for Gene Silencing and Delivery. Accounts of Chemical Research vol. 45, No. 7 (2012) 1100-1112. [cited by applicant]
Kim, T., et al. Bioreducible polymers with cell penetrating and endosome buffering functionality for gene delivery systems. Journal of Controlled Release 152 (2011) 110-119. [cited by applicant]
H. Akita, et al. Delivery of Nucleic Acids and Gene Delivery. Comprehensive Biomaterials, 2011 , pp. 411-444. [cited by applicant]
Jiang, X., et al. Disulfide-Containing Hyperbranched Polyethylenimine Derivatives via Click Chemistry for Nonviral Gene Delivery. Macromol. Chem. Phys. 2011, 212, 64-71. [cited by applicant]
Morille, M. et al. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 29 (2008) 3477-3496. [cited by applicant]
Meng, F., et al. Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials 30 (2009) 2180-2198. [cited by applicant]
Kim, S., et al. Reductive Degradation Behavior of Bioreducible Poly(disulfide amine) for Enhancing SiRNA Efficiency. Macromol. Biosci. 2010, 10, 898-905. [cited by applicant]
Tzeng, S. et al. Subtle changes to polymer structure and degradation mechanism enable highly effective nanoparticles for siRNA and DNA delivery to human brain cancer. Advanced Healthcare Materials 2013, 2(3): 46880. [cited by applicant]
Fire, A., et al. “Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans” Nature, 1998, 391, 806-811. [cited by applicant]
Green, J. et al, “A Combinatorial Polymer Library Approach Yields Insight into Nonviral Gene Delivery” Acc. Chem. Res., 2008, 41, 749-759. [cited by applicant]
Peng, Q. et al “Disulfide cross-linked polyethylenimines (PEI) prepared via thiolation of low molecular weight PEI as highly efficient gene vectors” Bioconjugate Chem., 2008, 19, 499-506. [cited by applicant]
Van der Aa, L. et al, “Optimization of poly(amido amine)s as vectors for siRNA delivery” J. Controlled Release, 2011, 150, 177-186. [cited by applicant]
Yin, Q. et al. “Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(B-amino esters)” Biomaterials, 2012, 33, 6495-6506. [cited by applicant]
Lee, J. et al, “Gold, poly (β-amino ester) nanoparticles for small interfering RNA delivery” Nano Lett., 2009, 9, 2402-2406. [cited by applicant]
Ravin, R. et al. Shear Forces During Blast, Not Abrupt Changes in Pressure Alone, Generate Calcium Activity in Human Brain Cells. PLoS One 2012, 7, e39421. [cited by applicant]
International Search Report dated Feb. 14, 2014; International Application No. PCT/US2013/066901. [cited by applicant]
Pieter Vader et al., “Disulfide-Based Poly(amido amine)s for siRNA Delivery: Effects of Structure on siRNA Complexation, Cellular Uptake, Gene Silencing and Toxicity,” Pharm. Res. 2011, vol. 28, pp. 1013-1022. [cited by applicant]
Dhananjay Jere et al., “Poly(b-amino ester) as a carrier for si/shRNA delivery in lung cancer cells,” Biomaterials, 2008, vol. 29, pp. 2535-2547. [cited by applicant]
M. C. Pedroso de Lima, S. Simoes, P. Pires, H. Faneca, and N. Duzgunes, “Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications,” Advanced Drug Delivery Reviews, vol. 47, pp. 277-294, … [cited by applicant]
N. D. Sonawane, F. C. Szoka, and AS. Verkman, “Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes,” Journal of Biological Chemistry, vol. 278, pp. 44826-44831, Nov. 7, 2003. [cited by applicant]
D. G. Anderson, A. Akinc, N. Hossain, and R. Langer, “Structure/property studies of polymeric gene delivery using a library of poly (beta-amino esters),” Molecular Therapy, vol. 11, pp. 426-434, Mar. 2005. [cited by applicant]
G. T. Zugates, W. Peng, A. Zumbuehl, S. Jhunjhunwala, Y.H. Huang, R. Langer, J. A Sawicki, and D. G. Anderson, “Rapid Optimization of Gene Delivery by Parallel End-modification of Poly(beta-amino ester)s,” A1ol Ther, vo… [cited by applicant]
M. M. O. Sullivan, J. J. Green, and T. M. Przybycien, “Development of a novel gene delivery scaffold utilizing colloidal gold-polyethylenimine conjugates for DNA condensation,” Gene Therapy, vol. 10, pp. 1882-1890, Oct.… [cited by applicant]
A. J. Ewald, A. Brenot, M. Duong, B. S. Chan, and Z. Werb, “Collective Epithelial Migration and Cell Rearrangements Drive Mammary Branching Morphogenesis” Dev Cell. vol. 14(4) pp. 570-581, Apr. 2008. [cited by applicant]
Rutz, S., and Scheffold, A., Arthritis Res Ther 2004, 6, 78-85 (2004). [cited by applicant]
David Oupick et al., “Redox-Responsive Polymer-Based Gene Delivery Systems”, Gene and Cell Therapy, Therapeutic Mechanisms and Strategies, Third Edition, Chapter 13, Nancy Smyth Templeton, CRC Press 2008. [cited by applicant]
Bhise, N. et al “The relationship between terminal functionalization and molecular weight of a gene delivery polymer and transfection efficacy in mammary epithelial 2-D cultures and 3-D organotypic cultures”, Biomateria… [cited by applicant]
Tzeng, S. et al “Synthetic poly (ester amine) and poly (amido amine) nanoparticles for efficient DNA and siRNA delivery to human endothelial cells”, Int. J. Nanomed., 2011, 6, 3309-3322. [cited by applicant]
Tzeng, S. et al, “Non-viral gene delivery nanoparticles based on Poly(β-amino esters) for treatment of glioblastoma” Biomaterials, 2011, 32, 5402-5410. [cited by applicant]
Wu, W. et al, MicroRNA and Cancer: Current Status and Prospective. Int. J. Cancer 2007, 120, 953-60. [cited by applicant]
Boussif, O. et al. A Versatile Vector for Gene and Oligonucleotide Transfer into Cells in Culture and in-Vivo-Polyethylenimine. Proc. Natl. Acad. Sci. 1995, 92, 7297-7301. [cited by applicant]
Kawasaki, H. et al, Short Hairpin Type of Dsrnas That are Controlled by Trnaval Promoter Significantly Induce RNAi-Mediated Gene Silencing in the Cytoplasm of Human Cells. Nucleic Acids Res. 2003, 31, 700-707. [cited by applicant]
Tzeng, S. et al, Subtle Changes to Polymer Structure and Degradation Mechanism Enable Highly Effective Nanoparticles for siRNA and DNA Delivery to Human Brain Cancer. Adv. Healthcare Mater. 2013, 2, 467. [cited by applicant]
Kozielski, K. et al, A Bioreducible Linear Poly(Beta-Amino Ester) for siRNA Delivery. Chem. Commun. 2013, 49, 5319-5321. [cited by applicant]
Vader, P. et al, Disulfide-Based Poly(Amido Amine)s for siRNA Delivery: Effects of Structure on siRNA Complexation, Cellular Uptake, Gene Silencing and Toxicity. Pharmaceut. Res. 2011, 28, 1013-1022. [cited by applicant]
Wyman, T. et al, Design, Synthesis, and Characterization of a Cationic Peptide That Binds to Nucleic Acids and Permeabilizes Bilayers. Biochemistry 1997, 36, 3008-3017. [cited by applicant]
Mok, H. et al, Self-Crosslinked and Reducible Fusogenic Peptides for Intracellular Delivery of siRNA. Biopolymers 2008, 89, 881-888. [cited by applicant]
Sunshine, J. et al, Effects of Base Polymer Hydrophobicity and End-Group Modification on Polymeric Gene Delivery. Biomacromolecules 2011, 12, 3592-3600. [cited by applicant]
Lopez-Bertoni et al, Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell Regulating miRNAs Inhibit Glioblastoma Growth and Prolong Survival. Nano Lett. 2018;18:4086-94. [cited by applicant]
Binder. Functional MRI is a valid noninvasive alternative to Wada testing. Epilepsy Behav. Feb. 2011;20(2):214-22. [cited by applicant]
Papanicolaou et al., Is it time to replace the Wada test and put awake craniotomy to sleep? Epilepsia. May 2014;55(5):629-632. [cited by applicant]
Rapoport et al., Focused ultrasound-mediated drug delivery to pancreatic cancer in a mouse model. J Ther Ultrasound. Jul. 1, 2013:1:11. [cited by applicant]
Rapoport. Drug-Loaded Perfluorocarbon Nanodroplets for Ultrasound-Mediated Drug Delivery. Adv Exp Med Biol. 2016:880:221-41. [cited by applicant]
Remington: The Science and Practice of Pharmacy. Lippincott Williams & Wilkins., (2005), ed. 21. 14 pages. [cited by applicant]
Timbie et al., Drug and gene delivery across the blood-brain barrier with focused ultrasound. J Control Release. Dec. 10, 2015:219:61-75. [cited by applicant]